

Neonatal Medication Guideline

Clinical Guideline

Amoxicillin with Clavulanic Acid

Policy developed by: SA Maternal & Neonatal Clinical Community of Practice

Approved by

Safety & Quality Strategic Governance Committee on: 28 April 2017

Next review due: 30 April 2020

Summary The purpose of the Amoxicillin with Clavulanic Acid Neonatal Medication Guideline is to guide nursing, medical and pharmacy staff in the dosing and administration of amoxicillin with clavulanic acid.

Keywords Amoxicillin with clavulanic acid, neonatal medication guideline, co-amoxiclav, amoxicillin, amoxicillin, sepsis, infection, penicillin, clinical guideline, Amoxicillin with Clavulanic Acid Neonatal Medication Guideline

Policy history Is this a new policy? **N**
Does this policy amend or update an existing policy? **Y v1.0**
Does this policy replace an existing policy? **N**
If so, which policies?

Applies to All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN

Staff impact All Clinical, Medical, Midwifery, Nursing, Students, Allied Health, Emergency, Mental Health, Pathology, Pharmacy

PDS reference CG009

Version control and change history

Version	Date from	Date to	Amendment
1.0	November 2012	April 2017	Original version
2.0	28 April 2017	Current	Complete review

© Department for Health and Ageing, Government of South Australia. All rights reserved.

South Australian Neonatal Medication Guidelines

amoxicillin with clavulanic acid

amoxicillin 80mg, clavulanic acid 11.4mg/mL mixture

© Department of Health, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

Co-amoxiclav, amoxycillin with clavulanic acid

Dose and Indications

Infection due to susceptible organisms

Oral

Dose according to amoxicillin content

Duo® product, 12.5–22.5 mg/kg every 12 hours

Length of treatment should be guided by pathology and clinical picture; however in proven sepsis treatment should continue for a minimum of 7 days.

Preparation and Administration

Oral

There are brands available refer to product information for reconstitution volume.

The reconstituted solution is usually stable for 7 days stored under refrigeration; however this may change according to brand available. Please consult product information.

Amoxicillin with clavulanic acid is best given with feeds to minimise gastrointestinal irritation.

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-379-0
South Australian Maternal, Neonatal & Gynaecology Clinical Network
27/04/2017
South Australian Neonatal Medication Guidelines Workgroup at:
Health:NeoMed@sa.gov.au

amoxicillin with clavulanic acid

amoxicillin 80mg, clavulanic acid 11.4mg/mL mixture

Adverse Effects

Common

Diarrhoea, secondary infection especially during prolonged treatment, transient increases in liver enzymes and bilirubin

Infrequent

Vomiting, Clostridium difficile-associated disease

Rare

Rash, black tongue, neurotoxicity, bleeding, blood dyscrasias, rash, cholestatic hepatitis

Anaphylactic shock is not commonly seen in neonates.

Monitoring

- > Hepatic function if treatment lasts for >14 days.

Practice Points

- > Amoxicillin with clavulanic acid provides some anaerobic cover

Version control and change history

PDS reference: OCE use only

Version	Date from	Date to	Amendment
1.0	November 2012	April 2017	Original version
2.0	April 2017	Current	Complete review

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-379-0
South Australian Maternal, Neonatal & Gynaecology Clinical Reference Group
27/04/2017
South Australian Neonatal Medication Guidelines Workgroup at:
Health:NeoMed@sa.gov.au